Opinion|Videos|June 5, 2024
Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.
Advertisement
Video content above is prompted by the following question(s):
- Discuss the safety profiles reported across these three trials. Were there any new or unexpected toxicities observed with the novel therapies compared to standard treatments?
Advertisement
Related to this article
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
3
Health System Pharmacies Keep Patients on GLP-1 Therapy
4
Community Oncologists Ready to Innovate, but Barriers Remain
5